ArticleEBioMedicine2019

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.

Anna Laurenzana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.